ログイン
Language:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

  1. 原著論文

Optimal radiation dose to induce an abscopal effect by combining carbon-ion radiotherapy and anti-CTLA4 antibody

https://repo.qst.go.jp/records/2001412
https://repo.qst.go.jp/records/2001412
2e25ea7a-6771-467a-99a7-c286c43cda5e
名前 / ファイル ライセンス アクション
1a6cb481cd6a349111829239f6e2ac06.pdf Optimal_radiation_dose_to_induce_an_abscopal_effec.pdf (1.7 MB)
アイテムタイプ 学術雑誌論文 / Journal Article(1)
公開日 2025-05-09
タイトル
タイトル Optimal radiation dose to induce an abscopal effect by combining carbon-ion radiotherapy and anti-CTLA4 antibody
言語 en
言語
言語 eng
資源タイプ
資源タイプ識別子 http://purl.org/coar/resource_type/c_6501
資源タイプ journal article
著者 Liqiu Ma

× Liqiu Ma

Liqiu Ma

Search repository
Yang Li

× Yang Li

Yang Li

Search repository
Sakamoto Yoshimitsu

× Sakamoto Yoshimitsu

Sakamoto Yoshimitsu

Search repository
Xie Lin

× Xie Lin

Xie Lin

Search repository
Suzuki Saaya

× Suzuki Saaya

Suzuki Saaya

Search repository
Yoshida Yukari

× Yoshida Yukari

Yoshida Yukari

Search repository
Li Sui

× Li Sui

Li Sui

Search repository
Gang Guo

× Gang Guo

Gang Guo

Search repository
Jialing Wen

× Jialing Wen

Jialing Wen

Search repository
Wangcai Ren

× Wangcai Ren

Wangcai Ren

Search repository
Kazuhiro Kakimi

× Kazuhiro Kakimi

Kazuhiro Kakimi

Search repository
Osada Kensuke

× Osada Kensuke

Osada Kensuke

Search repository
Takahashi Akihisa

× Takahashi Akihisa

Takahashi Akihisa

Search repository
Shimokawa Takashi

× Shimokawa Takashi

Shimokawa Takashi

Search repository
抄録
内容記述タイプ Abstract
内容記述 Background and purpose: Although carbon-ion radiotherapy (CIRT) has led to good outcomes, controlling metastasis is still crucial for improving overall survival. This study aimed to evaluate the effectiveness of by two combinations, one of CIRT and anti-CTLA4 antibody, the other of CIRT and anti-PD-1 antibody, applied at different radiation doses for distal tumour and metastasis suppression.
Materials and methods: Murine cancer cells (colon carcinoma Colon-26 cells for experiments and osteosarcoma LM8 cells for verification) were grafted into both sides of the hind legs of syngeneic mice. Right-side tumours were irradiated with 3 Gy or 10 Gy CIRT while the left-side tumours were not irradiated, followed by the administration of the anti-CTLA4 antibody or anti-PD-1 antibody. The diameter of the tumours in both legs was measured 3 times per week after irradiation. The number of pulmonary metastases was evaluated within 3 weeks after irradiation.
Results: Compared with the control group, the high-dose group showed promising anti-cancer benefits in terms of both irradiated tumours and lung metastasis, but neither 10 Gy CIRT combined with the anti-CTLA4 antibody nor 10 Gy CIRT combined with the anti-PD-1 antibody suppressed the growth of distant unirradiated tumours. In the low-dose group, the effect on primary tumour control was slightly weaker than that in the high-dose treatment group, but significant suppressive effects on both distant unirradiated tumours and metastases were observed following 3 Gy CIRT combined with anti-CTLA4 antibody treatment. Specifically, the volume of distant unirradiated tumours decreased by 40 % compared with that of the control group, and no lung metastasis was observed.
Conclusion: Our findings suggest that there is an optimal dose range for the abscopal effect generated with the CIRT combined with anti-CTLA4 antibody, and it highlights a new opportunity for increased induction efficiency of the abscopal effect of combination therapy.
書誌情報 Neoplasia

発行日 2025-02
PubMed番号
識別子タイプ PMID
関連識別子 39674115
DOI
識別子タイプ DOI
関連識別子 10.1016/j.neo.2024.101099
戻る
0
views
See details
Views

Versions

Ver.1 2025-08-15 05:52:01.880054
Show All versions

Share

Share
tweet

Cite as

Other

print

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR 2.0
  • OAI-PMH JPCOAR 1.0
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX
  • ZIP

コミュニティ

確認

確認

確認


Powered by WEKO3


Powered by WEKO3